Vericel (VCEL) Preferred Stock Liabilities (2012 - 2013)
Vericel's (VCEL) quarterly Preferred Stock Liabilities came in at $42.9 million in Q2 2013, up 13.76% year-over-year from $37.7 million in Q2 2012, and little changed quarter-over-quarter from $42.9 million in Q1 2013.
Analysis
Vericel (VCEL) Preferred Stock Liabilities (2012 - 2013) Analysis & Trends
Vericel has disclosed Preferred Stock Liabilities across 2 years of filings, most recently posting $42.9 million for Q2 2013.
- In Q2 2013, Preferred Stock Liabilities rose 13.76% year-over-year to $42.9 million; the TTM figure through Jun 2013 stood at $42.9 million (up 13.76% YoY), while the FY2012 annual figure was $41.6 million, changed N/A from the prior year.
- Preferred Stock Liabilities came in at $42.9 million for Q2 2013 at Vericel, roughly flat from $42.9 million in the prior quarter.
- In the past five years, Preferred Stock Liabilities ranged from a high of $42.9 million in Q1 2013 to a low of $37.7 million in Q2 2012.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Krystal Biotech | 10.27 Bn | 9.43 Bn | 112.79 Mn | - |
| 2 | CRISPR Therapeutics AG | 5.17 Bn | 5.17 Bn | - | - |
| 3 | Iovance Biotherapeutics | 3.79 Bn | 3.49 Bn | 55.72 Mn | - |
| 4 | Legend Biotech | 3.68 Bn | 2.71 Bn | 251.50 Mn | - |
| 5 | uniQure | 3.05 Bn | 3.05 Bn | 5.49 Mn | - |
| 6 | Beam Therapeutics | 2.65 Bn | 2.65 Bn | - | - |
| 7 | Precigen | 2.44 Bn | 2.44 Bn | 52.17 Mn | - |
| 8 | Sarepta Therapeutics | 2.33 Bn | 1.53 Bn | 251.87 Mn | - |
| 9 | Vericel | 1.99 Bn | 1.83 Bn | 56.40 Mn | - |
| 10 | Taysha Gene Therapies | 1.97 Bn | 1.97 Bn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2013 | 42.88 Mn |
| Mar 31, 2013 | 42.88 Mn |
| Dec 31, 2012 | 41.61 Mn |
| Sep 30, 2012 | 40.36 Mn |
| Jun 30, 2012 | 37.69 Mn |